Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Executive Search and Leadership Advisory

Women Currently only 10% of Biotech Boards, Gender Study Shows

Authored by Karl Simpson In a new research study into gender diversity in biotech leadership, the findings convey a picture of significant male dominance in biotech boardroom. The research conducted by Liftstream, a specialist life sciences executive search practice, examined … Continue reading

Posted in Executive Appointments, Pharmaceutical business, Recruitment Market | Tagged , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Biotechnology must embrace a more diverse future of leadership

Authored by Karl Simpson When you talk to biotech entrepreneurs and sector investors, the topic of management and leadership is one that often features very strongly as the critical success factor. However, there is a dearth of research analysis into … Continue reading

Posted in Uncategorized | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Sutro Biopharma signs $1bn deal with Celgene

Authored by James Sheppard The San Francisco based biotech company Sutro Biopharma announced that it has signed a multi-year strategic collaboration and option to acquire agreement with the global biotech company Celgene. The deal follows an agreement signed between the … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , | Leave a comment

Moderna Therapeutics partners with Karolinska Institutet

Authored by James Sheppard The world renowned Karolinska Institutet has partnered with the Cambridge based biotech Moderna Therapeutics to develop new messenger RNA therapeutics for a range of serious diseases. The partnership will see the establishment of a new company called … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , | Leave a comment

Prosensa begins FDA submission process for DMD drug

Authored by James Sheppard The Dutch biotechnology company Prosensa has announced that it has begun the submission process for its Duchenne Muscular Dystrophy (DMD) drug Drisapersen with the FDA. Prosensa has hoped that it will fully file by the year … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , | Leave a comment

Astellas joins with Harvard for Gene Therapy push

Authored by James Sheppard The Japanese pharmaceutical giant Astellas announced that it was making its first efforts in the promising field of gene therapy. Astellas announced that it has signed a deal with Harvard Medical School investigator Constance Cepko to … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , | Leave a comment

Genentech pays $150m for NewLink’s oncology drug

Authored by James Sheppard Global biotech giant Genentech, part of Roche, announced a partnership with Iowa based biotech company NewLink Genetics. The partnership could be worth in excess of $1bn for NewLink if there assets hit certain predefined milestones. Genentech … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , | Leave a comment

Raze Therapeutics raises $24m in Series A funding

Authored by James Sheppard The venture capital giant Atlas Ventures announced that it has launched a newly formed biotech called Raze Therapeutics. Raze will be based in the Boston Biotech Cluster. Atlas was not alone in funding the company and … Continue reading

Posted in Executive Appointments, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment

Actavis bolsters infectious disease portfolio with Durata purchase

Authored by James Sheppard The global generics giant Actavis has announced a deal to acquire the Chicago based infectious disease specialist Durata Therapeutics. The deal is estimated to be worth in excess of $675m. The deal will see Actavis paying … Continue reading

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , | Leave a comment

Bicycle Therapeutics raises $32m for oncology assets

Authored by James Sheppard The Cambridge based biotech Bicycle Therapeutics announced that it raised $32m in venture financing to continue developing the company’s assets in oncology and ophthalmology. The funding round saw some of the industry’s biggest investor names with … Continue reading

Posted in M&A Finance and Funding, Pharmaceutical business | Tagged , , , , , , , , , , , , , , | Leave a comment




Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: ​+44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap